NCT Number: NCT00057317
Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 5 to 20 mg/day will be studied.
Looking for future studies?
Notify MeKey information
Conditions
Age range
35 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Pleven, Bulgaria
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age 35 to 75
- Type 2 diabetes for longer than 3 months
- HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening
- FPG (fasting plasma glucose) greater than 126 mg/dL at screening
- BMI (body mass index) less than 40 kg/square meter
Exclusion criteria
- Type I diabetes
- Type 2 diabetes patients currently treated with insulin
- Type 2 diabetes patients currently or previously treated with Actos, Avandia or Rezulin
- FPG (fasting plasma glucose) greater than 270 mg/dL at baseline
- Impaired liver or kidney function
- Triglycerides greater than 600 mg/dL
- Uncontrolled hypertension
- Pregnant or lactating women
- Women not using adequate contraception
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Hoffmann-La Roche
Industry
Registry information
Official study title
A Phase II, Randomized, Double-blind, Placebo-controlled Dose-ranging Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
Important dates
- Study start
- 2001
- Primary completion
- 2003
- Study completion
- 2003
- First posted
- Apr 1, 2003
- Registry last updated
- Aug 24, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Family Genetics Health Education and Healthy Behaviors
NCT01498276
Cancer, Cardiovascular Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsRisk Communication Within Mexican-American Families
NCT00469339
Breast Cancer, Breast Diseases
Houston, Texas, United States
View Trial DetailsGenetics of Type 2 Diabetes in West Africans
NCT00837122
Cardiovascular Diseases, Diabetes
Accra, Ghana
View Trial DetailsScreening and Characterization of Hearing Disorders in Diabetic Persons
NCT03437135
Diabetes, Diabetes Mellitus
Clermont-Ferrand, France
View Trial Details